Study #2021-0784
First-in-Human Assessment of Safety, Biodistribution and Pharmacokinetics of 18F-Fluoro-1-Naphthol (18F-4FN) for PET Imaging
MD Anderson Study Status
Enrolling
Treatment Agent
4-[18F]Fluoro-1-Naphthol
Description
18F-4FN represents a novel PET agent for imaging inflammation. Acute inflammatory signaling through the TLR axis recruits neutrophils and macrophages to inflammatory sites. Both cells activate the production of high energy reactive oxygen species/reactive nitrogen species (RONS), setting off a cascade that can be leveraged to detect the presence of these inflammatory cells by molecular imaging. 18F-4FN is efficiently oxidized by high energy RONS, leading to retention and accumulation in human neutrophil-like cells in vitro, and at the sites of acute inflammation in vivo. Like 18F-FDG, 18F-4FN clears rapidly through the kidney at 1 hr following i.v. injection
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Endocrine Neoplasia
Study phase:
Phase I
Physician name:
Sanjit Tewari
Department:
Nuclear Medicine
For general questions about clinical trials:
1-844-285-5619
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.